The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2019

Filed:

Aug. 12, 2013
Applicant:

Randox Laboratories Ltd., Northern Ireland, GB;

Inventors:

Ivan McConnell, Northern Ireland, GB;

Stephen Peter Fitzgerald, Northern Ireland, GB;

John Lamont, Northern Ireland, GB;

Claran Richardson, Northern Ireland, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); G01N 33/68 (2006.01); C12N 9/10 (2006.01); G01N 33/70 (2006.01); G01N 33/92 (2006.01); C07K 14/81 (2006.01); C07K 14/475 (2006.01); G01N 33/573 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C07K 14/475 (2013.01); C07K 14/8139 (2013.01); C12N 9/104 (2013.01); G01N 33/573 (2013.01); G01N 33/6845 (2013.01); G01N 33/70 (2013.01); G01N 33/92 (2013.01); G01N 2333/47 (2013.01); G01N 2333/8139 (2013.01); G01N 2333/9108 (2013.01); G01N 2333/91188 (2013.01); G01N 2800/347 (2013.01); G01N 2800/50 (2013.01); G01N 2800/56 (2013.01);
Abstract

The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.


Find Patent Forward Citations

Loading…